In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices, GERD diagnostics, and the game-changing FDA approval for subcutaneous Tremfya in UC. Perfect for busy GI pros—actionable takeaways to level up your practice.

Key Segments and Highlights:

1. Guidelines Rundown:
   • BSG on IBD: Enhanced primary care pathways, CRC risk stratification, and patient adherence strategies to reduce post-colonoscopy cancers.
   • ACG on Gastric Premalignancy: First-ever guidance on atrophic gastritis, GIM, dysplasia—focus on H. pylori eradication and tailored surveillance.
   • BSG on Colorectal Surveillance: Clear start/stop criteria post-polypectomy and in IBD, with tips for better patient buy-in.
   • AGA on Gastroparesis: 12 recs for diagnosis (scintigraphy) and treatments (prokinetics, G-POEM)—emphasizing personalized, multidisciplinary care.
   • Rome/International on Gastroparesis: Aligns with AGA, adds psychosocial screening and global non-pharma standards. Takeaway: Download from AGA/ACG/BSG sites and audit your protocols.
2. Research Pulse:
   • AI in Guideline Development (AGA Pilot): Cuts review time/costs dramatically for Crohn's biologics—use with human validation.
   • Targeted Drug Delivery: Nanoparticles for IBD/motility; watch for retention improvements.
   • H. pylori in MI Patients (ESC Data): Selective screening for high-risk antiplatelet users to curb GI bleeds.
   • EUS-Guided Gastroenterostomy: Standardization boosts success >90%; includes troubleshooting videos.
   • ASIDE Gastroenterology New Issue: Covers MMF in IBD, tofacitinib in peds UC, ESD aids, gastric cancer immunotherapy, and more.
   • Optical Enhancement Endoscopy RCT: 92% sensitivity for gastric metaplasia/neoplasia—upgrade for high-risk screens.
   • Hospital Affiliation Costs Study: Independents save 20-30% without quality loss; implications for value-based care. Takeaway: Subscribe to journals and experiment with AI cautiously.
3. Devices, Tech, and Approvals:
   • Medical AI Warnings: Address biases in GI datasets; great for polyps, risky for diverse monitoring.
   • ESGE on Bariatric Endoscopy: Devices like balloons and duodenal resurfacing—10-15% weight loss, low AEs; await long-term RCTs.
   • New GERD Tools: AFS (EGJ integrity), Milan (manometry), pHoenix (AET), COuGH RefluX (symptoms), Lyon (integrated phenotyping)—revolutionize grading.
   • FDA Approval: SubQ Tremfya for UC: 50% endoscopic response at Week 12; convenient induction sans IV. Takeaway: Train on AI pitfalls and adopt one GERD tool quarterly.

Themes & Standouts: Personalization dominates, AI as a tool (not takeover), tech for precision. Revamp gastroparesis care, smart H. pylori screens, and embrace subQ Tremfya.

Resources: Links to guidelines, studies, and journals in the episode description. Submit Q&A via app/email. Next up: UEG Week previews!

Sponsored by digestivejobs.com

https://www.gastroendopod.com